ArticleBioengineered2021
Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma.
Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- mCancer cell international · 2025Article
- Differences in the expression of CMTM3 and SSTR2 genes in right and left colon tumors: A molecular insight into colorectal cancer.Medical oncology (Northwood, London, England) · 2025Article
- Long non-coding rnas as key modulators of the immune microenvironment in hepatocellular carcinoma: implications for Immunotherapy.Frontiers in immunology · 2025Review
- Constructed Risk Prognosis Model Associated with Disulfidptosis lncRNAs in HCC.International journal of molecular sciences · 2023Article
- N6-methyladenosine (m6A)-connected lncRNAs are linked to survival and immune infiltration in glioma patients.Bioscience reports · 2023Article
- In vivo study revealed pro-tumorigenic effect of CMTM3 in hepatocellular carcinoma involving the regulation of peroxisome proliferator-activated receptor gamma (PPARγ).Cellular oncology (Dordrecht, Netherlands) · 2023Article
- Dynamic m6A-ncRNAs association and their impact on cancer pathogenesis, immune regulation and therapeutic response.Genes & diseases · 2023Review
- Glutamine metabolism genes prognostic signature for stomach adenocarcinoma and immune infiltration: potential biomarkers for predicting overall survival.Frontiers in oncology · 2023Article
- Current Opinions on the Relationship Between CMTM Family and Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2023Review
- M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.BMC cancer · 2022Article
- The role of N6-methyladenosine-modified non-coding RNAs in the pathological process of human cancer.Cell death discovery · 2022Review
- Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3.Bioengineered · 2022Article
- Novel necroptosis-related gene signature for predicting the prognosis of pancreatic adenocarcinoma.Aging · 2022Article
- Identification of m6A-Related lncRNA to Predict the Prognosis of Patients with Hepatocellular Carcinoma.BioMed research international · 2022Article
- Comprehensive Analysis of N6-Methyladenosine-Related Long Noncoding RNA Prognosis of Acute Myeloid Leukemia and Immune Cell Infiltration.Frontiers in genetics · 2022Article
- Identification of a novel gene signature with regard to ferroptosis, prognosis prediction, and immune microenvironment in osteosarcoma.Frontiers in genetics · 2022Article
- CMTM3 as a Potential New Immune Checkpoint Regulator.Journal of oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to illustrate the influence of N6-methyladenosine (m6A) long non-coding RNAs (lncRNAs) and immune cell infiltration in hepatocellular carcinoma (HCC). The relationship of lncRNAs and m6A was identified through gene expression analysis using PERL and R packages. The Kyoto Encyclopedia of Genes and Genomes gene expression enrichment analysis was performed via gene set enrichment analysis. Lasso regression was utilized to construct prognostic model. Differences in the tumor microenvironment and the immune correlation were analyzed to clarify immune cell infiltration in different clusters and their correlation with the clinical prognosis. Co-expression analysis showed that lncRNA expression was associated closely with m6A. Many lncRNAs were predictive risk factors of prognosis in HCC. m6A-lncRNAs were partially highly expressed in tumor tissue and could be used in a prognostic model to predict HCC prognosis, independent of other clinical characteristics. 'NOTCH SIGNALING PATHWAY' was most significantly enriched according to GSEA. CKLF-like MARVEL transmembrane domain-containing member 3 (CMTM3) was overexpressed in tumor tissue. Immune cells, such as activated CD4 memory T cells, CD8 T cells, and follicular helper T cells, highly infiltrated tissues in cluster 2. All related scores were higher in cluster 2, indicating a lower purity of tumor cells and higher density of immune-related cells in the tumor microenvironment. m6A-lncRNAs are closely related to HCC occurrence and progression. Corresponding prognostic models can help predict HCC prognosis. m6A-lncRNAs and the related immune cell infiltration in the tumor microenvironment can provide novel therapeutic targets in HCC that need to be further studied.[Figure: see text].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.